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Globally, ~71 million people are actively viraemic with the hepatitis 
C virus (HCV), with an estimated 10.15 million chronically infected 
in sub-Saharan Africa.[1] An estimated 600 000 South Africans have 
chronic hepatitis C, although the uncertainty intervals are wide.[2] 
Concomitantly, accurate prevalence data in the general population 
are generally lacking, although important data are emerging with 
regard to a high prevalence in high-risk or key populations.[3] The 
seroprevalence in the general population is thought to be <1%, and 
data from the blood transfusion services consistently point towards 
a low seroprevalence.[4] Key risk populations include people who 
inject/injected drugs (PWID), men who have sex with men (MSM) 
and the incarcerated population. A prospective study in HIV-positive 
MSM in Cape Town noted a hepatitis C seroprevalence of 5.6% and 
0.5% in the MSM and non-MSM groups, respectively.[5] In a smaller 
retrospective Cape Town study, 27% of injecting MSM were HCV 
antibody-positive; 37.5% were HIV co-infected.[6] More recently, a 
large countrywide seroprevalence study of key populations found a 
45% seroprevalence of HCV in PWID; 24.7% were HIV co-infected. [3] 
Of MSM, 2.7% were anti-HCV-positive and 40% HIV co-infected. 
Notably, HCV seroprevalence among sex workers was extremely low 
at 0.1%, but HIV and hepatitis B rates were high.
2019 marked 30 years since HCV was sequenced and cloned for 
the first time in 1989.[7] In 1991, 3 - 5 times weekly subcutaneous 
interferon for HCV demonstrated poor outcomes. Adding ribavirin 
improved response rates. In 2001, weekly pegylated interferon (Peg-
IFN) plus ribavirin showed significantly improved outcomes.[8,9] 
Overall, the achievement of a sustained virological response (SVR), 
defined as the absence of detectable HCV RNA at least 24 weeks 
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Background. An estimated 600 000 South Africans are chronically infected with hepatitis C virus (HCV). To date, accurate prevalence data 
are lacking, but emerging data suggest a significant burden in key populations. Historically, pegylated interferon and ribavirin treatment 
was challenging, with access limited. The advent of all-oral, short-course direct-acting antiviral (DAA) therapy has revolutionised the 
management of HCV, being well tolerated and highly effective, although initial cost was a prohibitive factor.
Objectives. To report our initial 2-year experience with DAA therapy at the University of Cape Town/Groote Schuur Hospital Liver Clinic, 
South Africa (SA).
Methods. Patients who were viraemic for HCV were offered access to DAA therapy. All relevant demographic, virological, serological and 
clinical laboratory data were captured in a registry. Liver fibrosis was assessed non-invasively with the FibroScan. DAA regimens were 
prescribed according to current guidance based on HCV genotype (GT), prior treatment history and degree of fibrosis. On treatment, 
virological response was recorded and a sustained virological response (SVR) was defined as an undetectable HCV RNA at least 12 weeks 
after the end of treatment.
Results. We report on the first 210 patients treated. Their median (interquartile range (IQR)) age was 52 (42 - 61) years and 65% were male, 
with men significantly younger than women at 50 (42 - 59) years v. 58 (47 - 67) years, respectively (p=0.001). All GTs were observed, with 
1 and 5 most prevalent at 45% and 20%, respectively, and GTs 2, 3 and 4 frequencies of 7%, 11% and 17%, respectively. Extensive subtype 
diversity for GTs 2 and 4 was present. The median (IQR) HCV viral load was log10 5.9 IU/mL (5.4 - 6.5). A significant proportion of patients 
(39%) had advanced fibrosis or cirrhosis, with 11% F3 fibrosis and 28% F4. Of those with cirrhosis, 12% were decompensated with Childs-
Pugh B or C disease. Of the patients, 19% were HIV co-infected and 2% HBV co-infected. In total, 13% were treatment experienced. The 
majority of patients were treated with sofosbuvir and ledipasvir (38%), daclatasvir (36%) or velpatasvir (± voxilaprevir, 9%). Less frequent 
combinations included partitaprevir, ritonavir, ombitasvir ± dasbuvir (11%) and sofosbuvir/ribavirin (5%). The per-protocol SVR was 96% 
(98% if sofosbuvir/ribavirin is excluded). The majority of treatment failures occurred with GT-4, notably subtype 4r. Mild side-effects were 
reported in 10% of patients, with none discontinuing therapy.
Conclusions. DAA therapy for HCV in a pan-genotypic group of patients, many with advanced liver disease, was highly effective. Our 
outcomes correspond with existing trial and real-world data for similar treatment. DAA therapy and access need rapid upscaling in SA, 
especially targeting key populations at point of care.
S Afr Med J 2020;110(2):112-117. https://doi.org/10.7196/SAMJ.2020.v110i2.14195
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after the end of treatment, ranged between 45% and 70%. SVR, an 
effective cure, was highly dependent on the HCV genotype (GT), 
in addition to other virological and patient factors. Interferon was 
contraindicated in many patients, and this, in addition to the cost 
and often 48-week duration of therapy, with significant adverse 
effects, made access to treatment impossible for many. The discovery 
of the HCV replicon system by Bartenschlager and colleagues[10,11] 
paved the way for the rapid development of new therapies. The 2006 
modification of the HCV replicon system heralded a revolution in 
therapeutic development, culminating in the first all-oral highly 
effective therapy for HCV, registered in 2014.[12] The targets of the 
three classes of direct-acting antivirals (DAAs) include the viral non-
structural components NS3/4A protease, NS5A replicase and NS5B 
polymerase.[13] Combinations of these DAAs, administered for 8 or 
12 weeks with or without ribavirin, effectively produce SVR rates well 
in excess of 90%. In most DAA registration studies, SVR rates exceed 
95%. Treatment is simple and well tolerated and has fundamentally 
changed the management of hepatitis C, allowing expanded access to 
previous categories of patients regarded as difficult or not possible to 
treat with Peg-IFN and ribavirin-based therapy.[14]
Initially, however, cost was a major factor, denying access to most. 
In South Africa (SA), access through a variety of mechanisms early 
on, albeit on a limited basis, has been possible.[15]
Objectives
To report our initial experience in patients with chronic hepatitis C 
infection treated with DAA therapy.
Methods
Patients with proven HCV infection and referred to the Liver Clinic 
at the University of Cape Town and Groote Schuur Hospital were 
prospectively captured in a registry in terms of all relevant demographic, 
serological and virological data. All patients were screened with a 
laboratory-based anti-HCV antibody test and if positive had active 
viraemia confirmed with an HCV quantitative viral load (VL) (Cobas 
Amplicor (Roche, Switzerland) or Xpert (Cepheid, USA)). In those 
with confirmed viraemia, genotyping was performed with NS5B 
amplification, sequencing and analysis using the geno2pheno online 
algorithm (https://www.geno2pheno.org). Additionally, all patients 
were screened for HIV (if not known to be HIV-positive) and hepatitis 
B surface antigen (HBsAg; Roche, Switzerland). HIV-infected patients 
were required to be stable on antiretroviral therapy with a suppressed 
HIV VL to be eligible for DAA therapy. In those positive for HBsAg, 
hepatitis B e antigen (HBeAg) and hepatitis B VL (Roche) were 
measured to assess HBV replication. HIV-negative patients who 
were HBV co-infected were placed on either lamivudine or tenofovir, 
with DAA therapy only initiated once HBV VL was undetectable. 
As a routine, all patients had baseline renal and liver function tests, 
including an alpha-fetoprotein (AFP) level. At baseline, all patients 
had hepatitis C viral sequencing performed to evaluate whether pre-
existing resistance-associated substitutions (RASs) or variants were 
present. Standard population-based Sanger sequencing was used. 
While on treatment, repeat HCV VL, alanine transaminase (ALT) and 
creatinine were assessed at 4 weeks and at the end of treatment. SVR 
was assessed by the absence of detectable HCV RNA at least 12 weeks 
after the end of treatment (SVR12).
Liver fibrosis assessment was performed using vibration-controlled 
transient elastography (FibroScan; Echosens, France) to acquire a 
kPa liver stiffness score, and patients were classified as having F0, 
F1, F2, F3 or F4 fibrosis. Pretreatment ultrasound screening for 
hepatocellular carcinoma (HCC) was performed in all patients.
Access to DAA therapy was achieved through various sources. 
These included: (i) a compassionate use programme from AbbVie 
Pharma for paritaprevir/ritonavir/ombitasvir/dasabuvir for patients 
with HCV GT-1 or GT-4 infections; (ii) a donation of sofosbuvir 
and daclatasvir from Médecins Sans Frontières; (iii) the Groote 
Schuur Hospital pharmacy, by utilising the existing budget for 
Peg-IFN/ribavirin for the procurement of DAA therapies; and 
(iv) patients privately funded or paying out of pocket. Therapies 
included originator and, where available, generic DAAs from 
India of sofosbuvir, sofosbuvir/ledipasvir, sofosbuvir/velpatasvir, 
sofosbuvir/daclatasvir and, more recently, sofosbuvir/velpatasvir/
voxilaprevir. Importantly, at present no DAAs are registered by the 
South African Health Professions Regulation Authority (SAHPRA), 
and as such, in treating all patients, named patient approvals via 
Section 21 certificates were obtained. Treatment protocols followed 
existing American Association for the Study of Liver Disease, 
European Association for the Study of Liver Disease and local 
treatment guidelines. In principle, patients had 12 weeks of therapy 
with ribavirin added to treatment regimens of sofosbuvir/ledipasvir, 
sofosbuvir/daclatasvir or sofosbuvir/velpatasvir in those with 
cirrhosis. In clinically problematic patients likely to be intolerant 
of ribavirin, treatment was extended to 24 weeks without ribavirin. 
We performed a per protocol analysis of our experience in the first 
2.5 years of using DAA therapies.
Ethics approval
The study was approved by the University of Cape Town Human 
Research Ethics Committee (ref. no. R045/2014).
Statistical analysis
All values are expressed as medians and interquartile ranges (IQRs) 
for continuous variables. Baseline and on-treatment data were 
summarised using standard descriptive characteristics. Where 
appropriate, differences between qualitative parameters were explored 
using the Wilcoxon rank-sum test. Statistical analysis was performed 
using Statistica version 13.5.0.17 (Dell, USA).
Results
Table 1 shows the baseline demographics of the first 210 patients 
who completed DAA therapy in an ongoing treatment programme. 
Almost two-thirds were men, who were significantly younger than 
women at the time of treatment (median age 50 years v. 58 years; 
p=0.0018). The GT distribution reaffirms the pan-genotypic nature 
of HCV in SA, with GTs 1 and 5 predominating (45% and 20%, 
respectively). However, a significant proportion, 17%, were GT-4 
infected. These patients were mostly black (47%), with more than half 
originating from other countries in sub-Saharan Africa, including 
Rwanda, the Democratic Republic of the Congo (DRC), Cameroon, 
Malawi and Ethiopia. Overall, almost 40% of patients had advanced 
fibrosis (F3) or cirrhosis (F4) at baseline. In addition, 13% of patients 
were treatment experienced and 19% were HIV co-infected, with 
4 patients (2%) HBV-HCV co-infected. Of those who were cirrhotic, 
12% were Childs-Pugh class B or C. The likely mode of acquisition of 
hepatitis C (Table 1) is in keeping with known risk factors. Notably, 
no clear risk factor was identified in 26% of patients. Table 2 shows 
the diversity of HCV GT subtypes, with stark diversity noted in 
GTs 2 and 4. Table 3 confirms the wide array of DAA regimens 
used, although NS5A/NS5B combination therapies predominated. 
These included sofosbuvir in combination with either daclatasvir, 
ledipasvir or velpatasvir, with the majority of patients accessing 
generic medicines. The overall SVR12 was 96%. When those who 
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failed sofosbuvir/ribavirin (a combination no longer used for non-
GT-2 patients) were excluded from this calculation, the overall 
SVR12 was 98%. Looking specifically at GTs 1b, 2 and 5, the SVR 
was 100%. Notably, a non-SVR was observed in patients with GTs 3 
and 4, the majority GT-4 and in particular subtype 4r (Table 4). In 
keeping with the efficacy of DAA therapy, 84% of patients were virally 
undetectable and below the lower level of quantification at 4 weeks 
of therapy. Paralleling this was a significant and rapid normalisation 
of serum ALT at week 4, with further improvement at the end of 
treatment (p<0.0001). Of note, a significant decline in serum AFP 
from baseline to the end of treatment (p<0.0001), a phenomenon not 
typically reported, was observed (Table 5).
Discussion
For the first time, we report local experience with DAA therapy 
for hepatitis C. As anticipated, key populations such as PWID 
and MSM constituted high proportions of our cohort (27% and 
17%, respectively). Furthermore, despite a historically safe blood/
blood products supply system, haemophiliacs and those who 
received blood/blood products before 1992 were at risk, with 17% 
of our cohort sharing this as a risk factor.[16-19] Additionally, we have 
demonstrated that unsafe medical practices are a risk factor (10%). 
In a significant proportion of patients (26%) no clear mode of 
acquisition was identified. In this group, black African patients were 
most likely to not have a clearly identifiable acquisition risk factor 
(p<0.00001). Reasons for this finding are entirely unclear and may 
suggest exposure to unsafe medical or possibly traditional practices as 
a potential risk factor for HCV transmission. These factors certainly 
warrant further study to guide screening policies in SA and sub-
Saharan Africa as a whole.
Globally, of the 71 million patients chronically infected with 
HCV, approximately half have HCV GTs other than GT-1.[20] SA is 
a multi-genotypic country, with two studies confirming that GTs 1 
and 5 were most prevalent and GTs 2, 3 and 4 also prevalent.[21,22] 
Table 1. Baseline demographics of DAA-treated patients (N=210)
Age (years), median (IQR) (males v. females) 52 (42 - 61) (50 (42 - 59) v. 58 (47 - 67); p=0.0018)




Mixed ancestry 46 (22)
Asian 8 (4)







HCV RNA (log10 IU/mL), mean (IQR) 5.9 (5.4 - 6.5)
Previous HCV treatment, n (%) 28 (13)
Peg-IFN and RBV 20/28 (72)
Protease inhibitor, Peg-IFN and RBV 1/28 (3)
Previous DAA failure 7/28 (25)
HIV-positive,* n (%) 39 (19)
HBsAg-positive, n (%) 4 (2)






Decompensated cirrhosis,‡ n/N F4 (%) 7/59 (12) 
Mode of HCV acquisition, n (%)
Unknown 54 (26)
PWID 56 (27)
Previous blood/blood products 36 (17)
MSM 36 (17)
Unsafe medical practice 22 (10)
Healthcare workers 5 (2.4)
Perinatal 1 (0.5)
DAA = direct-acting antiviral; IQR = interquartile range; GT = genotype; HCV = hepatitis C virus; Peg-IFN = pegylated interferon; RBV = ribavirin; HBsAg = hepatitis B surface antigen;  
PWID = people who inject/injected drugs; MSM = men who have sex with men.
*All patients on antiretroviral therapy and HIV virally suppressed.
†Determined by liver biopsy or vibration-controlled transient elastography (FibroScan).
‡Childs-Pugh class B or C. 
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We noted a similar GT distribution, although marked GT-4 subtype 
diversity was also observed. Most GT-4 subtype diversity is observed 
in sub-Saharan Africa, with GT-4r, for example, frequently found in 
the DRC and Rwanda.[23] Most of our black GT-4 patients originated 
from these and other African countries, explaining our observed 
diversity. Other unusual subtypes, e.g. GT-2c or GT-4d, clustered in 
a number of individuals with similar HCV transmission risk. These 
occurred exclusively in MSM, strongly supporting potential network 
transmission. Rapidly linking these patients to treatment is crucial in 
breaking the network of transmission.[24]
Our SVR rate of 96%, in keeping with existing trial as well as real-
world experience data, is encouraging.[25] When we excluded our 
failed sofosbuvir/ribavirin patients from this assessment, SVR was 
98%. Sofosbuvir/ribavirin was an early therapy that demonstrated 
an improvement well above Peg-IFN/ribavirin therapy and offered 
the first ‘all-oral’ option for patients. However, overall SVR rates 
(except for GT-2) fell short of the now accepted >90% benchmark 
SVR rate expected of DAA therapy, and this combination has now 
mostly been abandoned in favour of more efficacious combinations. 
It remains a reasonable option for GT-2, but patients need to tolerate 
12 weeks of ribavirin. If they are unable to do so, ribavirin-free 
options exist.[26]
When contextualised in terms of the baseline demographics of 
our patients, our outcomes confirm treatment efficacy in what were 
previously termed ‘difficult-to-treat’ patients, with almost 40% having 
advanced fibrosis or cirrhosis. Of the 28% with cirrhosis, 12% had 
Childs-Pugh class B or C disease. In addition, almost 20% were HIV 
co-infected, and 13% were treatment experienced. All these factors 
would have significantly affected SVR rates in the Peg-IFN/ribavirin 
era of therapy, with some ineligible for therapy. DAA therapy now 
negates these factors, and very few patients, if any, pose clinical 
challenges to therapy. Furthermore, therapy was well tolerated, with 
no patients discontinuing therapy due to adverse effects. In keeping 
with most trial data, 10% reported a side-effect, mostly minor and 
including headache and mild sleep disturbances. These typically 
occur early in therapy and usually abate.[27]
Serum transaminases significantly declined between week 4 and the 
end of treatment and mirrored the rapid loss of HCV RNA. Another 
observation was the significant decline in serum AFP, particularly 
Table 2. Hepatitis C GT subtype diversity


























Table 3. DAA regimens (N=206)
n (%)
Sofosbuvir/ribavirin 10 (5)
Partitaprevir, ritonavir, ombitasvir + ribavirin  8 (4)




+ ribavirin† 12/75 (16)
Sofosbuvir/ledipasvir‡ 80 (38)




DAA = direct-acting antiviral.
*Exclusively generic therapy.
†Ribavirin added to DAA regimen if F4 fibrosis/cirrhosis present.
‡63% received brand-name therapy, 37% one of two generics.
Table 4. Outcomes of DAA-treated patients (N=210)
n (%)
HCV RNA <LLOQ during treatment period
At week 4 176 (84)
At week 12 208 (99)
At least 12 weeks after EOT (SVR) 202 (96)







SVR per treatment regimen
Sofosbuvir/ribavirin 8/10 (80)
Partitaprevir, ritonavir, ombitasvir + ribavirin 7/8 (88)







Virological failure (N=8 without SVR)
During treatment 2/8 (25)
After treatment 6/8 (75)
Adverse events‡ 22 (10)
Discontinued therapy because of adverse events 0
DAA = direct-acting antiviral; HCV = hepatitis C virus; LLOQ = lower level of 
quantification of HCV RNA (lower than detectable limit); EOT = end of treatment;  
SVR = sustained virological response; GT = genotype.
*Non-SVR in subtype 4r (4 patients) and 4v (1 patient) only.
†1 GT-5 and 1 GT-3 patient only completed 5 weeks of treatment – both achieved SVR12.
‡Headache, asthenia, sleep disturbances.
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in patients with cirrhosis. This phenomenon has been described 
previously, and it is an independent predictor of declining HCC risk in 
patients with advanced fibrosis or cirrhosis.[28-30] Importantly, patients 
with cirrhosis, despite SVR, warrant lifelong HCC surveillance.
Focusing specifically on GTs, SVR12 was 100% in GTs 1b, 2 and 
5. A single patient with GT-1a failed therapy and was successfully 
retreated with a sofosbuvir/simeprevir/ribavirin regimen. SVR was 
not achieved in 2 patients with GT-3a. One was treated with 
sofosbuvir/ribavirin and the other with sofosbuvir/daclatasvir. 
Problems with sofosbuvir/ribavirin are noted above, but failure 
to achieve SVR in a second patient on sofosbuvir/daclatasvir was 
probably due to the presence of cirrhosis as well a particularly 
problematic RAS mutation (Y93H). This mutation poses potential 
resistance to NS5A inhibitors, especially in GT-3-infected patients.[31] 
Concerningly, several treatment failures occurred in GT-4 patients, 
including subtypes 4r (4 patients) and 4v (1 patient). Our experience, 
together with newly published data from Rwanda and France,[32,33] 
suggests that GT-4r has a reduced sensitivity to NS5A inhibitors, 
especially ledipasvir. In the Rwanda study,[32] only 54% of GT-4r 
patients achieved SVR. Furthermore, the latest data suggest that 
the wide diversity of GT-4 and the array of baseline RAS mutations 
pose a therapeutic challenge that would disproportionally affect sub-
Saharan Africa, given GT-4 and its subtype diversity prevalence.[34] 
A better understanding and further study of what regimen is best 
to treat GT-4r and other potentially problematic subtypes is needed.
Most of our patients were treated with sofosbuvir-based therapy 
in combination with one of three NS5A inhibitors, viz. daclatasvir, 
ledipasvir or velpatasvir. Given the lack of registration of DAAs by 
the SAHPRA to date, cost issues and the lack of initial availability of 
originator therapies, generics were sourced from Indian-based generic 
manufacturers. In our cohort, originator and generic therapies were 
equally effective. Once originator drug products are registered, generic 
availability, as a Section 21 therapy, will cease. This will pose a significant 
barrier to potential access for many if costs are not negotiated with 
manufacturers by government, in advance of registration. In particular, 
price parity between public and private sector pricing must be sought. 
A price differential cannot be the norm if the elimination of viral 
hepatitis is the objective in SA, as it is globally. This objective, as per the 
World Health Organization 2016 adopted global health sector strategy 
policy, aims to eliminate viral hepatitis by 2030.[35] SA adopted its own 
costed plan in this regard in 2018.[36] We recommend that SA utilise 
pangenotypic DAA therapies for its strategic plan through sofosbuvir 
plus daclatasvir or velpatasvir. This strategy omits the potential need 
for genotyping in the treatment cascade, allowing for rapid linkage to 
care. Routine HCV Sanger sequencing in DAA-naive patients prior to 
treatment is not recommended.
Underpinning the gigantic therapeutic advance of DAA therapy is 
the number of people who have been linked to care. Over a >10-year 
period, our clinic treated 77 patients with Peg-IFN/ribavirin with an 
overall SVR rate of 75%. This was achieved through careful patient 
selection by limiting access to those with difficult-to-treat clinical and 
virological characteristics. In 2.5 years, three times more people were 
treated with excellent outcomes, many of them previously regarded 
as difficult to treat.
Conclusions
DAA therapy has fundamentally changed the approach to the 
management of hepatitis C and provided impetus towards the 
elimination of hepatitis C. However, many challenges remain, 
including access and the need for new models and approaches to the 
delivery of care to key populations. The current model of care based 
at a tertiary-level specialist clinic is not feasible for the upscaling of 
treatment. What we have demonstrated is that even in our resource-
constrained environment, linking patients to this curative therapy 
is possible and has the potential to be expanded to all levels of care.
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